Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; complet ...
Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash ...
Even as investors, founders and shoppers alike pay close attention to better-for-you food innovation, the reality on shelves remains intense and uncertain. 2024 data shows that only about 29% of new ...
Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 ...
XPro™ is a next-generation, selective soluble TNF inhibitor designed to selectively neutralize soluble TNF (sTNF) and restore ...
Australia’s medicine safety officials have warned the government they are flying blind on the use of puberty blocker drugs for gender-distressed minors.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results